Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio

Fineline Cube Dec 29, 2025
Company Deals

Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal

Fineline Cube Dec 29, 2025
Company Deals

Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing

Fineline Cube Dec 29, 2025
Company Deals

TJ Biopharma Partners with Zhejiang Lab to Develop AI‑Driven Ultra‑Long‑Acting Growth Hormone

Fineline Cube Dec 29, 2025
Company Deals

HBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next‑Generation RDCs in Precision Oncology

Fineline Cube Dec 29, 2025
Policy / Regulatory

Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders

Fineline Cube Dec 30, 2025
Company Drug

Sino Biopharmaceutical’s TDI01 Enrolls First IPF Patient in World’s First ROCK2 Inhibitor Phase III Trial

Fineline Cube Dec 30, 2025
Company Drug

TJ Biopharma and Jumpcan Secure BE Trial Approval for Localized Eftansomatropin in China

Fineline Cube Dec 30, 2025
Company Deals

Siemens Healthineers and Stryker Forge Neurovascular Robotics Alliance

Fineline Cube Sep 18, 2025

Siemens Healthineers (ETR: SHL) and Stryker (NYSE: SYK) today announced a strategic partnership to co‑develop...

Drug Policy / Regulatory

China CDE Seeks Public Feedback on 98th Batch of Reference Standards for Generic Drugs

Fineline Cube Sep 18, 2025

The China Center for Drug Evaluation (CDE) has published a draft list of the 98th...

Company Deals

Mabwell Bioscience Teams With Aditum Bio to Launch Kalexo Bio, Inc., Targeting $1 B in Cardio siRNA Deal

Fineline Cube Sep 18, 2025

Mabwell Bioscience (SHA: 688062) announced a strategic partnership with Aditum Bio Fund 3, L.P. to form Kalexo...

Company Deals

Cook Medical & Siemens Healthineers Partner to Launch First Radiation‑Free iMRI Suite

Fineline Cube Sep 17, 2025

Cook Medical and Siemens Healthineers (ETR: SHL) today announced a strategic collaboration aimed at redefining...

Company

Eli Lilly Unveils $5 B Virginia Facility to Scale Bioconjugate & Antibody Production

Fineline Cube Sep 17, 2025

Eli Lilly (NYSE: LLY) announced plans to construct a $5 billion manufacturing complex just west of...

Company

AstraZeneca China Decentralises Medical Affairs, Signals Shift in Global Strategy

Fineline Cube Sep 17, 2025

AstraZeneca (AZ; NASDAQ: AZN) China announced a sweeping re‑organisation that removes the country‑level Head of...

Company Drug

Ascletis Pharma Reports 28‑Day ASC30 Study Results at EASD

Fineline Cube Sep 17, 2025

Ascletis Pharma Inc. (HKG: 1672) announced that its Phase Ib multiple‑ascending‑dose (MAD) study of the oral...

Company Deals

Hisun Pharma Secures China Rights to Ascentawits’ First‑In‑Class Drug AST‑3424

Fineline Cube Sep 17, 2025

Zhejiang Hisun Pharmaceutical Co., Ltd. (SHA: 600267) announced today that it has signed an exclusive...

Policy / Regulatory

Guangdong Launches 5‑Year Plan to Streamline Import of Urgently Needed Drugs and Medical Devices

Fineline Cube Sep 17, 2025

The Guangdong Provincial Drug Administration and the Guangdong Provincial Health Commission jointly announced the “Administrative...

Company

GSK to Invest $30 B in the United States Over Five Years, Building Advanced Biopharma Facilities

Fineline Cube Sep 17, 2025

GlaxoSmithKline (GSK; NYSE: GSK) announced today a $30 billion U.S. investment program that will fund research...

Company Drug

Novo Nordisk to File US Approval for High‑Dose Wegovy, Aiming to Match Lilly’s Zepbound

Fineline Cube Sep 17, 2025

Novo Nordisk A/S (NYSE: NVO) has announced plans to seek U.S. regulatory approval for a...

Company Deals

Suzhou‑Based InnoBM Partners with Qilu Pharmaceutical on BM601 Metallic Embolic Microsphere

Fineline Cube Sep 17, 2025

InnoBM Pharmaceuticals Co., Ltd. and Qilu Pharmaceutical Co. have inked a collaboration agreement to commercialize...

Company Deals Drug

Shanghai Henlius Biotech Negotiates Potential Sale of HLX43 ADC to Johnson & Johnson and Roche

Fineline Cube Sep 17, 2025

Henlius Biotech Inc. (HKG: 2696) is reportedly in talks with global pharmaceutical giants Johnson & Johnson (J&J,...

Company Deals

Shenzhen Mindray Eyes $1 B+ Hong Kong IPO With Huatai, JPMorgan On Board

Fineline Cube Sep 17, 2025

Shenzhen Mindray Bio‑Medical Electronics Co. has confirmed that Huatai Securities and JPMorgan Chase & Co. are the...

Company Deals

Duoning Bio Secures Global License for Upstream Bio’s Biochemical Analyzer Portfolio

Fineline Cube Sep 17, 2025

Duoning Biotechnology Co., Ltd. announced a strategic partnership with Upstream Bio Inc., granting Duoning an...

Drug

CSPC’s ALMB-0166 Approved for Phase II Trials in Parkinson’s Disease

Fineline Cube Sep 17, 2025

CSPC Pharmaceutical Group Limited (HKG: 1093), a China-based company, announced on September 15, 2025, that...

Company Drug

Nanjing Leads Biolabs Doses First Patient in Opamtistomig Melanoma Trial

Fineline Cube Sep 17, 2025

Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced today that the first patient has been...

Company Drug

AstraZeneca Launches Ultomiris in China for gMG and NMOSD Treatments

Fineline Cube Sep 17, 2025

UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has announced the launch of Ultomiris (ravulizumab), a...

Company

AstraZeneca Pauses GBP 200m Cambridge R&D Investment Amid UK Funding Cuts

Fineline Cube Sep 17, 2025

On September 12, 2025, AstraZeneca (AZ; NASDAQ: AZN) confirmed it has paused its GBP 200m...

Company Drug

Novo Nordisk Rybelsus Gains Cardio Benefit from SOUL Trial

Fineline Cube Sep 16, 2025

Novo Nordisk A/S (NYSE: NVO) announced that the European Medicines Agency (EMA)’s Committee for Medicinal Products...

Posts pagination

1 … 38 39 40 … 602

Recent updates

  • Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders
  • Sino Biopharmaceutical’s TDI01 Enrolls First IPF Patient in World’s First ROCK2 Inhibitor Phase III Trial
  • TJ Biopharma and Jumpcan Secure BE Trial Approval for Localized Eftansomatropin in China
  • Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio
  • Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders

Company Drug

Sino Biopharmaceutical’s TDI01 Enrolls First IPF Patient in World’s First ROCK2 Inhibitor Phase III Trial

Company Drug

TJ Biopharma and Jumpcan Secure BE Trial Approval for Localized Eftansomatropin in China

Company Deals

Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.